
Recursion Pharmaceuticals (RXRX) Stock
Data driven biotech company using computers to find medicines. Here's the price, business snapshot, and what's worth knowing about Recursion Pharmaceuticals in November 2026.
Recursion Pharmaceuticals-A (RXRX) is a clinical-stage biotechnology company combining machine learning, high-throughput biology and automation to accelerate drug discovery. The firm builds large biological datasets and applies computational models to identify potential therapeutic candidates and biomarkers across multiple disease areas. Investors should note Recursion is platform-driven rather than a traditional commercial drugmaker: value is tied to scientific progress, partnerships and successful advancement of candidates through preclinical and clinical stages. The company has collaboration agreements and may generate milestone and royalty revenue in the future, but like many biotechs it has historically run at a loss while investing in R&D and infrastructure. Key risks include clinical and regulatory setbacks, heavy capital needs, and volatility in development timelines. For long-term investors this is a high-risk, high-uncertainty opportunity that could benefit from breakthroughs in AI-enabled discovery, but outcomes are uncertain and diversification and suitability assessment are important before considering exposure.
Recursion Pharmaceuticals (RXRX) Stock Forecast
Analyst price target, next 12 months
$8.80
+202.4% vs today's $2.91
Price range over the last 12 months
Close to its 12-month low
Analysts covering Recursion Pharmaceuticals have a consensus 12-month target of $8.80, above the current price of $2.91.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 18 Nov 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Recursion Pharmaceuticals' stock with a target price of $8.82, indicating potential growth.
Financial Health
Recursion Pharmaceuticals is generating moderate revenue and cash flow but has a low profit margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
AI-led Discovery
Recursion’s platform analyses large biological datasets to identify candidates faster than traditional methods, though platform promises depend on scientific validation and successful translation.
Partnerships & Deals
Collaborations can provide non-dilutive funding and milestones, potentially de‑risking some programmes, but deal execution and future revenue remain uncertain.
Early-stage Pipeline
A diverse preclinical and clinical pipeline offers multiple pathways to value, yet clinical setbacks or longer timelines can materially affect prospects.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.